Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Double-blind, Placebo-controlled Study of VIS410 in Uncomplicated Influenza A Infection
2015-004546-26Phase 2Completed
- Sponsor
- Visterra
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection comparing VIS410 single-dose IV with Placebo IV (2 arms). Primary endpoint: Safety and tolerability of VIS410. Started Dec 2016; status: completed.
02
Drugs
VIS410
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2015-004546-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004546-26.